{
      "Rank": 21,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Intervention: Intravenousling (IV) AD-MSC in 10 patients with type 1 diabetes mellitus."
      ],
      "ArmGroupInterventionName": [
            "Combination Product: adipose-derived messenchymal stem cell"
      ],
      "ArmGroupLabel": [
            "Adipose-derived messenchymal stem cell (AD-MSC)"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05308836"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to evaluate the safety of intravenously (IV) administered adipose-derived mesenchymal stem cell (AD-MSC) in patients with type 1 diabetes mellitus (T1D)"
      ],
      "BriefTitle": [
            "Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment"
      ],
      "CentralContactEMail": [
            "v.liemnt@vinmec.com",
            "v.kiennt25@vinmec.com"
      ],
      "CentralContactName": [
            "Liem T Liem, Prof",
            "Kien T Nguyen, MsC"
      ],
      "CentralContactPhone": [
            "0986565015",
            "0386958552"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "UNKNOWN"
      ],
      "CollaboratorName": [
            "Gwoxi Stem cell applied technology Company"
      ],
      "CompletionDate": [
            "October 30, 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Type 1 Diabetes"
      ],
      "ConditionAncestorId": [
            "D000044882",
            "D000008659",
            "D000004700",
            "D000001327",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Glucose Metabolism Disorders",
            "Metabolic Diseases",
            "Endocrine System Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC18",
            "BC19",
            "All",
            "BC20"
      ],
      "ConditionBrowseBranchName": [
            "Nutritional and Metabolic Diseases",
            "Gland and Hormone Related Diseases",
            "All Conditions",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Diabetes",
            "Type 1 Diabetes"
      ],
      "ConditionBrowseLeafId": [
            "M6267",
            "M6269",
            "M10791",
            "M24556",
            "M7014",
            "M3781",
            "M9352"
      ],
      "ConditionBrowseLeafName": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 1",
            "Metabolic Diseases",
            "Glucose Metabolism Disorders",
            "Endocrine System Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000003920",
            "D000003922"
      ],
      "ConditionMeshTerm": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 1"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Adipose derived mesenchymal stem cells (AD-MSCs) has many advantages, i.e. the greater ease of access and harvesting by means such as subcutaneous lipoaspiration, a much less painful procedure than harvesting bone marrow stem cells, and a much less ethical concern because they are harvested from autologous fat. The purpose of this study is to evaluate the safety of intravenously (IV) administered adipose-derived mesenchymal stem cell (AD-MSC) in treatment 10 patients with type 1 diabetes mellitus (T1D) at Vinmec International Hospital, Hanoi, Vietnam."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatient diagnosed T1D (according to the instructions of the Ministry of Health No: 5481/QD-BYT dated December 30, 2020)\nAged from 5 years and over.\nBe within 12 months of diagnosis with T1D\n\nBlood test:\n\nFasting blood glucose > 7 mmol / L,\n7,5% < HbA1C <10%.\nHave at least one antibodies associated with T1D such as ICA or GAD\nThe patient does not have other serious acute illness requiring treatment\nThe patient agrees to use stem cell transplant for treatment\nThe patient's parent (parent or legal guardian) can read, write, understand the ICF form and agree to sign a consent to participate in the study.\n\nExclusion Criteria:\n\nHaving evidence related to renal dysfunction: creatinine > 1.5 mg/dl or (>133 mmol/L) for boys, creatinine > 1.4 mg/dl or (>124 mmol/L) for girls\nIn case of kidney failure. Proteinuria within the range of nephrotic syndrome (>3.5 g/day or ratio of protein/creatinine in urine >2.7)\nIn case of kidney failure\nHaving severe infection or infected with hepatitis B virus, hepatitis C virus, HIV virus, or tuberculosis\nCardiovascular disease, respiratory disease (pulmonary, fibrosis, chronic respiratory failure), liver disease, cancer or neurological disease\nBlood clotting disorders (INR> 1,5, PTT> 40, PT> 15).\nTaking any anticoagulant\nTaking systemic steroids\nParticipate in another clinical study involving experimenting drugs and/or medical equipment\nHistory of allergic reaction to anesthetic agents and/or antibiotics"
      ],
      "EnrollmentCount": [
            "10"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Adipose-derived messenchymal stem cell (AD-MSC)"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "adipose-derived messenchymal stem cell"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Combination Product"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Diabetes Adipose-derived mesenchymal stem cell"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "April 4, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "March 31, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Vinmec Research Institute of Stem Cell and Gene Technology"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Hanoi"
      ],
      "LocationContactEMail": [
            "v.liemnt@vinmec.com"
      ],
      "LocationContactName": [
            "Liem T Nguyen, Prof"
      ],
      "LocationContactPhone": [
            "(+84 4) 3 974 3556"
      ],
      "LocationContactPhoneExt": [
            "1420"
      ],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "Vietnam"
      ],
      "LocationFacility": [
            "Vinmec Research Institute of Stem Cell and Gene Technology"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "10000"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "5 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase I Open Label Clinical Trial to Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Vinmec Research Institute of Stem Cell and Gene Technology"
      ],
      "OrgStudyId": [
            "ISC20.01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Vinmec Research Institute of Stem Cell and Gene Technology"
      ],
      "OverallOfficialName": [
            "Liem T Nguyen, Prof"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "October 30, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Safety is recognized as number of adverse events (AE) and serious adverse events (SAE) appear from the time that patients sign in ICF"
      ],
      "PrimaryOutcomeMeasure": [
            "Safety measure"
      ],
      "PrimaryOutcomeTimeFrame": [
            "up to the 6-month period following treatment"
      ],
      "ReferenceCitation": [
            "Zhang Y, Chen W, Feng B, Cao H. The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis. Aging Dis. 2020 Feb 1;11(1):141-153. doi: 10.14336/AD.2019.0421. eCollection 2020 Feb. Review.",
            "Araujo DB, Dantas JR, Silva KR, Souto DL, Pereira MFC, Moreira JP, Luiz RR, Claudio-Da-Silva CS, Gabbay MAL, Dib SA, Couri CEB, Maiolino A, Rebelatto CLK, Daga DR, Senegaglia AC, Brofman PRS, Baptista LS, Oliveira JEP, Zajdenverg L, Rodacki M. Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study. Front Immunol. 2020 Jun 2;11:993. doi: 10.3389/fimmu.2020.00993. eCollection 2020."
      ],
      "ReferencePMID": [
            "32010488",
            "32582156"
      ],
      "ReferenceType": [
            "result",
            "result"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "A hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin",
            "Fasting blood glucose (FPG) measures the levels of glucose (sugar) in the blood",
            "C-peptide levels",
            "Blood insulin",
            "Insulin dose"
      ],
      "SecondaryOutcomeMeasure": [
            "HbA1c",
            "Fasting blood glucose (FPG)",
            "C-peptide levels",
            "Blood insulin",
            "Insulin dose"
      ],
      "SecondaryOutcomeTimeFrame": [
            "up to the 6-month period following treatment",
            "up to the 6-month period following treatment",
            "up to the 6-month period following treatment",
            "up to the 6-month period following treatment",
            "up to the 6-month period following treatment"
      ],
      "SeeAlsoLinkLabel": [
            "Heterologous Adipose-Derived Mesenchymal Stem Cells and Vitamin D Supplementation in Patients with Recent-Onset Type 1 Diabetes Mellitus-Six Months Follow-Up"
      ],
      "SeeAlsoLinkURL": [
            "https://diabetesjournals.org/diabetes/article/67/Supplement_1/1112-P/54170/Heterologous-Adipose-Derived-Mesenchymal-Stem"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "October 4, 2021"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "March 2022"
      ],
      "StdAge": [
            "Child",
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 4, 2022"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "February 25, 2022"
      ],
      "StudyFirstSubmitQCDate": [
            "March 31, 2022"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}